GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Cyclically Adjusted PB Ratio

Assembly Biosciences (FRA:V7B) Cyclically Adjusted PB Ratio : 0.25 (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-09-22), Assembly Biosciences's current share price is €16.65. Assembly Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €67.30. Assembly Biosciences's Cyclically Adjusted PB Ratio for today is 0.25.

The historical rank and industry rank for Assembly Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:V7B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.27   Max: 11.75
Current: 0.26

During the past years, Assembly Biosciences's highest Cyclically Adjusted PB Ratio was 11.75. The lowest was 0.10. And the median was 0.27.

FRA:V7B's Cyclically Adjusted PB Ratio is ranked better than
80.2% of 606 companies
in the Biotechnology industry
Industry Median: 1.605 vs FRA:V7B: 0.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Assembly Biosciences's adjusted book value per share data for the three months ended in Jun. 2024 was €5.078. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €67.30 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Assembly Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Assembly Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Cyclically Adjusted PB Ratio Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.32 0.77 0.32 0.19 0.13

Assembly Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.14 0.13 0.18 0.19

Competitive Comparison of Assembly Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted PB Ratio falls into.



Assembly Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Assembly Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=16.65/67.3
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Assembly Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=5.078/132.5538*132.5538
=5.078

Current CPI (Jun. 2024) = 132.5538.

Assembly Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201409 50.592 100.428 66.776
201412 53.412 99.070 71.464
201503 85.028 99.621 113.137
201506 81.398 100.684 107.163
201509 77.837 100.392 102.774
201512 75.937 99.792 100.867
201603 68.366 100.470 90.197
201606 62.349 101.688 81.274
201609 55.891 101.861 72.732
201612 52.687 101.863 68.562
201703 43.983 102.862 56.679
201706 34.779 103.349 44.607
201709 27.295 104.136 34.744
201712 56.959 104.011 72.590
201803 48.874 105.290 61.530
201806 44.398 106.317 55.355
201809 92.674 106.507 115.338
201812 87.152 105.998 108.986
201903 79.142 107.251 97.814
201906 72.344 108.070 88.734
201909 65.904 108.329 80.641
201912 90.629 108.420 110.803
202003 83.808 108.902 102.010
202006 86.760 108.767 105.734
202009 83.717 109.815 101.052
202012 69.741 109.897 84.119
202103 62.143 111.754 73.709
202106 52.735 114.631 60.980
202109 48.673 115.734 55.747
202112 37.282 117.630 42.012
202203 33.229 121.301 36.312
202206 29.101 125.017 30.855
202209 25.600 125.227 27.098
202212 19.152 125.222 20.273
202303 15.155 127.348 15.775
202306 11.604 128.729 11.949
202309 8.915 129.860 9.100
202312 6.874 129.419 7.040
202403 5.470 131.776 5.502
202406 5.078 132.554 5.078

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assembly Biosciences  (FRA:V7B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Assembly Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences Headlines

No Headlines